2018-004446-42: Maintenance Of aNtiplatElet Therapy in patients with coronary stenting undergoing surgery Mantenimento della terapia antiaggregante nei pazienti portatori di stent coronarico candidati a chirurgia |
|
|
| Not yet recruiting | 2 | 140 | Europe | Cangrelor, [CANGRELOR. Si segnala che il codice ATC di seguit, Powder for solution for infusion, Kengrexal 50 mg polvere per concentrato per soluzione per iniezione/infusione | AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO, Chiesi Farmaceutici S.p.A., Fondazione GISE Onlus | Patients a least 18 years of age on DAPT per standard of care who are planned to undergo non deferrable cardiac and non cardiac surgery which will require discontinuation of a P2Y12 inhibitor. Subjects with stent implantation within 12 months of an ACS and within 6 months of elective stent implantation for stable CAD, or subjects subjected to elective PCI within the previous 12 months if still in DAPT because considered high-risk thrombotic will be included. Pazienti di almeno 18 anni di età in trattamento con DAPT, candidati a chirurgia non differibile (cardiaca o non cardiaca) che richiedano la sospensione perioperatoria dell’inibitore P2Y12. Verranno inclusi soggetti con impianto di stent entro 12 mesi da una sindrome coronarica acuta e entro 6 mesi dall’impianto elettivo di stent per coronaropatia stabile, o soggetti sottoposti a PCI elettiva entro i 12 mesi precedenti se ancora in DAPT perchè considerati ad alto rischio trombotico., Patients a least 18 years of age on DAPT per standard of care who are planned to undergo non deferrable cardiac and non cardiac surgery which will require discontinuation of a P2Y12 inhibitor. Pazienti di almeno 18 anni di età in trattamento con DAPT, candidati a chirurgia non differibile (cardiaca o non cardiaca) che richiedano la sospensione perioperatoria dell’inibitore P2Y12., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2020-005149-18: Antiplatelet treatment with Cangrelor in patients presenting with myocardial infarction Antiblutplättchentherapie mit Cangrelor in Patienten mit Herzinfarkt |
|
|
| Not yet recruiting | 2 | 64 | Europe | Cangrelor, Cangrelor, Powder and solvent for solution for injection/infusion, Kengrexal | Medical University of Vienna, Medical University of Vienna | ST-Elevation Myocardial Infarction ST-Hebungs Myokardinfarkt, Heart attack Herzinfarkt, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Active, not recruiting | 2 | 228 | RoW | Cangrelor, Kengreal | National Heart Centre Singapore, Tan Tock Seng Hospital, National University Hospital, Singapore, Khoo Teck Puat Hospital, Changi General Hospital, Sengkang General Hospital | STEMI | 12/22 | 12/22 | | |